Closed Solicitation · DEPARTMENT OF HEALTH AND HUMAN SERVICES
AI Summary
The FDA intends to award a sole source purchase order for one Whole Genome Sequencing instrument, specifically the Illumina MiSeq i100 System or an equivalent. Interested parties must submit capability statements demonstrating how their products meet the specified requirements by March 26, 2026.
NOTICE OF INTENT TO SOLE SOURCE
Description
This notice is issued for informational and market research purposes only and does not constitute a solicitation.
The FDA intends to award a sole source Firm-Fixed-Price purchase order for one (1) Whole Genome Sequencing instrument.
The Government is considering the Illumina MiSeq i100 System or equal product that meets all salient characteristics identified in the Statement of Work (SOW). Offerors proposing equal products shall demonstrate how the proposed product meets each of the salient characteristics
The instrument shall include a minimum one (1) year manufacturer’s warranty covering parts and labor.
Response Instructions
Interested parties shall submit capability statements demonstrating ability to meet requirements.
Offerors proposing an equivalent must clearly demonstrate how requirements are met.
Response Deadline
March 26, 2026, at 2:30 PM ET
Submission
Contracting Officer: Iris Johnson
Email: Iris.Johnson1@fda.hhs.gov
ILLUMINA MISEQ I100 SYSTEM OR EQUAL is a federal acquisition solicitation issued by DEPARTMENT OF HEALTH AND HUMAN SERVICES. Review the full description, attachments, and submission requirements on SamSearch before the response deadline.
SamSearch Platform
AI-powered intelligence for the right opportunities, the right leads, and the right time.